Detalles de la búsqueda
1.
Individualized follicle-stimulating hormone dosing and in vitro fertilization outcome in agonist downregulated cycles: a systematic review.
Acta Obstet Gynecol Scand
; 95(12): 1333-1344, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27687487
2.
Added value of anti-Müllerian hormone in prediction of menopause: results from a large prospective cohort study.
Hum Reprod
; 30(8): 1974-81, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26082477
3.
The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome.
Curr Opin Obstet Gynecol
; 22(3): 193-201, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20407372
4.
Using individual patient data to adjust for indirectness did not successfully remove the bias in this case of comparative test accuracy.
J Clin Epidemiol
; 68(3): 290-8, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25475365
5.
Antimüllerian hormone as predictor of reproductive outcome in subfertile women with elevated basal follicle-stimulating hormone levels: a follow-up study.
Fertil Steril
; 100(3): 831-8, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23755952
6.
Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach.
Hum Reprod Update
; 19(1): 26-36, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23188168
7.
Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis.
Fertil Steril
; 100(2): 420-9.e7, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23721718
Resultados
1 -
7
de 7
1
Próxima >
>>